The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | COVALENT-101: BMF-219 in patients with R/R AML, DLBCL & multiple myeloma
Farhad Ravandi, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the rationale and design of the COVALENT-101 study (NCT05153330) which evaluates the tolerability and efficacy of BMF-219, a novel oral irreversible menin inhibitor, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Research funding – BMS/Celgene, Amgen, Astex/Taiho, Syros, Prelude, Abbvie, Xencor Consultant – BMS, Abbvie, Novartis, AstraZeneca, Taiho, Jazz
